Compare IMMR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | BNR |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 233.6M |
| IPO Year | 1999 | 2020 |
| Metric | IMMR | BNR |
|---|---|---|
| Price | $6.82 | $20.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.25 | N/A |
| AVG Volume (30 Days) | ★ 573.1K | 64.2K |
| Earning Date | 12-19-2025 | 11-20-2025 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | $75,749,382.00 |
| Revenue This Year | $988.71 | $136.32 |
| Revenue Next Year | $109.72 | N/A |
| P/E Ratio | $3.33 | ★ N/A |
| Revenue Growth | ★ 338.21 | 5.56 |
| 52 Week Low | $5.65 | $2.18 |
| 52 Week High | $9.07 | $24.18 |
| Indicator | IMMR | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 57.32 |
| Support Level | $6.36 | $19.49 |
| Resistance Level | $6.95 | $21.57 |
| Average True Range (ATR) | 0.21 | 1.80 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 62.33 | 60.45 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.